vTv Therapeutics (VTVT) Net Margin (2014 - 2026)

vTv Therapeutics has disclosed Net Margin across 11 years of filings, most recently posting 65.51% for Q1 2026.

• In Q1 2026, Net Margin changed N/A year-over-year to 65.51%; the TTM figure through Jun 2026 stood at 12.91% (up 11501650.0% YoY), while the FY2024 annual figure was 1815.34%, changed N/A from the prior year.
• Net Margin came in at 65.51% for Q1 2026 at vTv Therapeutics, up from 21376.47% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 65.51% in Q1 2026 to a low of 52722.22% in Q4 2022.
• Average Net Margin over 3 years is 18313.52%, with a median of 10931.49% recorded in 2024.
• The largest YoY upside for Net Margin was 2562222 bps in 2022 against a maximum downside of 2825556 bps in 2022.
• Over 3 years, Net Margin stood at 52722.22% in 2022, then surged by 59 bps to 21376.47% in 2024, then jumped by 100 bps to 65.51% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 65.51% in Q1 2026, 21376.47% in Q4 2024, and 486.5% in Q1 2024.